Low-dose apixaban to keep dialysis catheters working longer
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding a low dose of a blood thinner called apixaban (also known as Eliquis) to the standard solution used to keep dialysis catheters open will help prevent them from getting blocked. It could improve the reliability of your dialysis treatments and reduce the need for catheter replacements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have serious kidney disease that requires regular dialysis treatments.
- Your dialysis catheter (a flexible tube used for treatment) must have been in place for at least 8 days and be working well.
- You should be having dialysis 2 to 3 times a week at the study center.
- You must not have any active bleeding, stomach ulcers, or a recent history of bleeding problems.
- You should not be taking other blood thinners or certain antiplatelet medications during the study.
- You must be willing to follow the study rules and avoid pregnancy if that applies to you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to reopen blocked or narrowed fistulas (the blood vessels used for dialysis) in people on hemodialysis. The goal is to see how well it works and if it saves money compared to other treatments.
This trial studies a procedure to open up blocked or narrowed areas in the plastic tube (graft) used for dialysis. It aims to see if the procedure works well and if it is cost-effective for patients who have trouble completing dialysis because of graft issues.
This trial tests whether a blood-thinner medication called apixaban (Apiban) helps arteriovenous fistulas—surgically created connections in the arm for dialysis—develop and work better. If it helps fistulas mature faster and more reliably, it could reduce complications and improve treatment for kidney failure patients.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This study compares two strategies for managing atrial fibrillation (irregular heartbeat) in people on dialysis: one uses a blood thinner called apixaban to prevent strokes, and the other does not. The goal is to find out which approach is safer and more effective for this specific group.
This study tests whether dialysis can be done safely without using heparin (a blood thinner) in people with end-stage kidney disease. If successful, it could reduce the need for blood-thinning medications and their associated risks.
Hear when a new Hemodialysis Access Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.